An Open Label, Repeat Dose, Randomized, Two Period Crossover Study to Investigate the Potential Pharmacokinetic Interactions Between Oral GW679769 [casopitant] and Intravenous Cyclophosphamide in Cancer Patients.

Trial Profile

An Open Label, Repeat Dose, Randomized, Two Period Crossover Study to Investigate the Potential Pharmacokinetic Interactions Between Oral GW679769 [casopitant] and Intravenous Cyclophosphamide in Cancer Patients.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Casopitant; Cyclophosphamide
  • Indications Cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 02 Jul 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 20 May 2009 Planned end date changed from 1 Oct 2008 to 1 Oct 2009 as reported by ClinicalTrials.gov.
    • 09 Oct 2008 Actual start date changed from August to March 2005, reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top